RASSF10 Antibody
| Code | Size | Price |
|---|
| PSI-6371-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-6371-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
RASSF10 Antibody: Ras association domain-containing protein 10
Application Note:
RASSF10 antibody can be used for detection of RASSF10 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Background:
RASSF10 Antibody: RASSF10 is a member of the N-terminal Ras association domain-containing family of proteins, a family of tumor suppressor genes that are frequently epigenetically inactivated in cancer. These proteins consist of RASSF7-10 and are structurally distinct from RASSF1-6, containing the N-terminal Ras association domain but lacking the Sav/RASSF/Hippo protein interaction domains. While little is known of the function of RASSF10, it is inactivated in both childhood leukemia and gliomas. In secondary glioblastomas, RASSF10 methylation can be used as an independent prognostic associated with worst progression-free survival and overall survival.
Background References:
- Sherwood V, Manbodh R, Sheppard C, et al. RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis. Mol. Biol. Cell 2008; 19:1772-82.
- Hesson LB, Dunwell TL, Cooper WC, et al. The novel RASSF6 and RASSF10 candidate tumor suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol. Cancer 2009; 8:42
- Hill VK, Underhill-Day N, Krex D, et al. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene 2011; 30:30:978-89
Buffer:
RASSF10 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
RASSF10 antibody was raised against a 17 amino acid synthetic peptide near the amino terminus of human RASSF10.
The immunogen is located within amino acids 50 - 100 of RASSF10.
The immunogen is located within amino acids 50 - 100 of RASSF10.
NCBI Gene ID #:
644943
NCBI Official Name:
Ras association (RalGDS/AF-6) domain family (N-terminal) member 10
NCBI Official Symbol:
RASSF10
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_001073990
Protein GI Number:
304434798
Purification:
RASSF10 Antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer,Cell Cycle
SPECIFICITY:
RASSF10 antibody will not cross-react with other RAS association domain-containing family members.
Swissprot #:
A6NK89
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | SPT2 Peptide | PSI-6305P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|